Oculis Announced Disappointing Results For its OCS-01 Eye Drops

The Vaud-based company, which specializes in neuro-ophthalmology and ophthalmology, stated that the primary endpoint of the DIAMOND trials was not met, leading to the decision not to pursue regulatory approval with the FDA for OCS-01 in the treatment of diabetic macular edema.

Despite a well-tolerated safety profile, the lack of significant improvement in visual acuity raised concerns among investors.

Riad Sherif, CEO of Oculis, stated: “We are, of course, disappointed that the substantial and sustained reduction in retinal thickness observed in both trials did not translate into an improvement in best-corrected visual acuity (BCVA) at Week 52.”

“As we finalize our review of the DIAMOND programme data, we will strategically focus our resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER programme for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease.”

➡️ Source: Press Release | 📸 ©Oculis